Induction of apoptosis by piceatannol in human leukemic U937 cells through down-regulation of Bcl-2 and activation of caspases

Oncology Reports

Volumn 19, Issue 4, 2008, Pages 961-967

  Kim, Yeong Hoon ^a,b   Park, Cheol ^c,d   Lee, Jeong Ok ^a   Kim, Gi Young ^e   Lee, Won Ho ^c   Choi, Yung Hyun ^d,f   Ryu, Chung Ho ^a  

^a Gyeongsang National University   (South Korea)

^b Gyeongsangnam do Institute of Health and Environment   (South Korea)

^c Pusan National University   (South Korea)

^d Dong Eui University   (South Korea)

^e Jeju National University   (South Korea)

^f Dong Eui University   (South Korea)

Author keywords

Apoptosis; Bcl 2; Caspase 3; Piceatannol

Indexed keywords

BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 3 INHIBITOR; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PICEATANNOL; PROTEIN BCL 2; 3,3',4,5'-TETRAHYDROXYSTILBENE; ANTINEOPLASTIC AGENT; CASPASE 9; PROTEIN KINASE INHIBITOR; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL STRAIN U937; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 9; CELL SURVIVAL; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; STILBENES; U937 CELLS;

EID: 43849086307     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.4.961     Document Type: Article

References (31)

1. Walker PR and Sikorska M: New aspects of the mechanism of DNA fragmentation in apoptosis. Biochem Cell Biol 75: 287-299, 1997.
2. Robertson JD and Orrenius S: Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol 30: 609-627, 2000.
3. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
4. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
5. Takeda K, Stagg J, Yagita H, Okumura K and Smyth MJ: Targeting death-inducing receptors in cancer therapy. Oncogene 26: 3745-3757, 2007.
6. Bavaresco L, Fregoni C, Cantu E and Trevisan M: Stilbene compounds: from the grapevine to wine. Drugs Exp Clin Res 25: 57-63, 1999.
7. Roupe K, Teng XW, Fu X, Meadows GG and Davies NM: Determination of piceatannol in rat serum and liver microsomes: pharmacokinetics and phase I and II biotransformation. Biomed Chromatogr 18: 486-491, 2004.
8. Ferrigni NR, McLaughlin JL, Powell RG and Smith CR Jr: Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 47: 347-352, 1984.
9. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA and Burke MD: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778, 2002.
10. Geahlen RL and McLaughlin JL: Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 165: 241-245, 1989.
11. Fernandez LA, Torrealba J, Yagci G, Ishido N, Tsuchida M, Tae Kim H, Dong Y, Oberley T, Fechner J, Colburn MJ, Schultz J, Kanmaz T, Hu H, Knechtle SJ and Hamawy MM: Piceatannol in combination with low doses of cyclosporine A prolongs kidney allograft survival in a stringent rat transplantation model. Transplantation 74: 1609-1617, 2002.
12. Wong WS and Leong KP: Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta 1697: 53-69, 2004.
13. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S and Aggarwal BB: Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation. J Immunol 169: 6490-6497, 2002.
14. Islam S, Hassan F, Mu MM, Ito H, Koide N, Mori I, Yoshida T and Yokochi T: Piceatannol prevents lipopolysaccharide (LPS)-induced nitric oxide (NO) production and nuclear factor (NF)-κB activation by inhibiting IκB kinase (IKK). Microbiol Immunol 48: 729-736, 2004.
15. Jin CY, Moon DO, Lee KJ, Kim MO, Lee JD, Choi YH, Park YM and Kim GY: Piceatannol attenuates lipopolysaccharide-induced NF-κB activation and NF-κB-related proinflammatory mediators in BV2 microglia. Pharmacol Res 54: 461-467, 2006.
16. Su L and David M: Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 275: 12661-12666, 2000.
17. Larrosa M, Tomas-Barberan FA and Espin JC: The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr 43: 275-284, 2004.
18. Kumari AL, Ali AM, Das S, Pardhasaradhi BV, Varalakshmi CH and Khar A: Role of STAT3 and NFκB signaling in the serum factor-induced apoptosis in AK-5 cells. Biochem Biophys Res Commun 336: 860-867, 2005.
19. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dorken B, Schmalz HG, Daniel PT and Henze G: Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 15: 1735-1742, 2001.
20. Larrosa M, Tomas-Barberan FA and Espin JC: Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric Food Chem 51: 4576-4584, 2003.
21. Barton BE, Karras JG, Murphy TF, Barton A and Huang HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3: 11-20, 2004.
22. Ferreira MJ, Duarte N, Gyemant N, Radics R, Cherepnev G, Varga A and Molnar J: Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res 26: 3541-3546, 2006.
23. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994.
24. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
25. Rodriguez J and Lazebnik Y: Caspase-9 and APAF-1 form an active holoenzyme. Genes 13: 3179-3184, 1999.
26. Philchenkov A, Zavelevich M, Kroczak TJ and Los M: Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 26: 82-97, 2004.
27. Stennicke HR and Salvesen GS: Caspases - controlling intracellular signals by protease zymogen activation. Biochim Biophys Acta 1477: 299-306, 2000.
28. Roy N, Deveraux QL, Takahashi R, Salvesen GS and Reed JC: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16: 6914-6925, 1997.
29. Deveraux QL and Reed JC: IAP family proteins-suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
30. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1996.
31. Jiang C, Yang YF and Cheng SH: Fas ligand gene therapy for vascular intimal hyperplasia. Curr Gene Ther 4: 33-39, 2004.